How Dollars Are Used
The impact of the Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center has been enormous. Since its inception roughly 35 years ago, the Center has supported the training of over 100 young investigators. The accomplishments of these investigators in the course of their distinguished careers are far too numerous to count, but they include:
- Development of breakthrough drugs for rheumatoid arthritis (RA), juvenile arthritis, ankylosing spondylitis, and psoriatic arthritis
- Improved therapy for systemic lupus erythematosus (SLE)
- Identification of genes that predispose to various forms of arthritis and related autoimmune diseases, including RA, SLE, Sjogren’s Syndrome, and others.
- Discovery of basic biologic mechanism underlying arthritis and related autoimmune diseases that have pointed the way to new treatment strategies
- Establishment of international clinical trials networks
- Leadership in rheumatology research around the world, including faculty at major academic centers throughout the U.S., the Director of training in Arthritis and Rheumatology at the National Institutes of Health; the Director of the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA); past-presidents of national professional societies in the U.S. and elsewhere, including the American College of Rheumatology and its Research Foundation, the American Association of Immunologists, the Japan College of Rheumatology, and the Irish Society of Rheumatology.
- The highest awards for research from the Arthritis Foundation, the American Association of Immunologists, and the American College of Rheumatology